Viz.ai vs Recursion — Comparison

Viz.ai

Viz.ai closes the gaps between patients, clinicians, and life-saving treatments with its leading-edge AI-powered care coordination solution.

Press Release: Viz.ai Launches Viz Agent Studio Enabling Health Systems to Build and Scale Their Own AI Care Pathways Viz.ai uses artificial intelligence to accelerate care coordination, reducing systemic delays that stand between patients and life-saving treatments. It’s an innovative way of using technology to transform clinical workflow and patient care. Viz.ai was inspired by a patient who underwent a successful brain surgery and yet died because the surgery came too late. Systemic – but preventable – process delays had undermined the work of her care team. Frustrated by the unnecessary delays that had cost his patient her life, neurosurgeon Dr. Chris Mansi committed to finding a better way. Dr. Mansi joined forces with machine learning post-doc Dr. David Golan and together they founded Viz.ai, in 2016, with a goal of using artificial intelligence to make healthcare work faster and smarter. Not just to change it – but to radically transform it. We’re here for our patients, they impact every decision. We move quickly, because every patient deserves access to life saving treatment. We play by the rules and deliver excellence. We strive to build a culture of kindness. I do what I say I will do, I follow through and follow up. We’re always looking for talented individuals to join our team and our mission. Meet our executive team made up of industry experts, who cultivate our culture and lead the people who are driving the AI healthcare revolution. See for yourself how you can harness the power of AI to accelerate patient access to care through AI-powered care coordination.

Recursion

Dive into Recursion's innovative approach to decoding biology. Join our mission & explore what AI drug discovery companies can do. Contact us

Recursion was founded more than a decade ago on the idea that we could take images of cells and use these images to train artificial intelligence to understand the vast unknown biological space – the cellular disruptions driving disease – to use AI-drug discovery to reduce the massive 90% failure rate of traditional drug discovery. Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas Leveraging the Power of Patient Data in AI-Drug Discovery Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market

Viz.ai

Recursion

Viz.ai

Recursion

Viz.ai

Recursion